From a clinical standpoint, these findings support considering dual immunotherapy plus chemotherapy as a first-line option for fit patients with advanced NSCLC, especially those without driver mutations, even in PD-L1 low expressers. The gene discussed is CD274; the disease is non-small cell lung carcinoma.